Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler J, Limaye S, Riley S, Posner M. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. The Lancet Oncology 2013, 14: 257-264. PMID: 23414589, DOI: 10.1016/s1470-2045(13)70011-1.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyCisplatinCombined Modality TherapyDisease-Free SurvivalFemaleFluorouracilFollow-Up StudiesHead and Neck NeoplasmsHumansInduction ChemotherapyKaplan-Meier EstimateMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingTaxoidsConceptsHead and neck cancerChemoradiotherapy alone groupConcurrent chemoradiotherapyInduction chemotherapyChemoradiotherapy groupNeck cancerAlone groupOverall survivalLocally advanced head and neck cancerPatients treated with induction chemotherapyOpen-label phase 3 studyInduction chemotherapy to chemoradiotherapyCisplatin-based concurrent chemoradiotherapyRandomised phase 3 trialDiagnosed head and neck cancerCycles of TPFLocally advanced headMedian Follow-UpPrimary disease siteWHO performance statusPhase 3 studyAdvanced tumor stagePhase 3 trialBolus cisplatinSequential chemoradiotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply